

## REVIEW ARTICLE

# Probiotics and Disease: A Comprehensive Summary—Part 8, Gastrointestinal and Genitourinary Disorders

Heather J. Finley, DCN Candidate, RD, LD, CEDRD; Margaret G. Gasta, DCN Candidate, RDN, CCN;

Keren E. Dolan, DCN Candidate, CNS; Jessica M. Pizano, DCN Candidate, CNS;

Crystal M. Gossard, DCN Candidate, CNS; Christy B. Williamson, DCN Candidate, CNS;

Cathleen M. Burns, DCN Candidate, RD; Emily C. Parker, MS, RD; Elizabeth A. Lipski, PhD, CNS, CCN, BCHN, IFMCP

### Abstract

This article series provides a literature review of the disease-specific probiotic strains associated with gastrointestinal and genitourinary disorders studied in published clinical trials in humans and animals. This is not an exhaustive review. The table design allows for quick access to supportive data and will be helpful as a guide for both researchers and clinicians. The goal of the probiotics and disease series is to provide clinically useful tools. The first article (part 1) focused on mental health and neurological conditions; the second article (part 2) explored cultured and fermented foods that are commonly available in the United States; the third article (part 3) explored the relationship between bacterial strains and 2 of the most prevalent diseases we have in modern society: cardiometabolic disease and fatigue syndromes; the fourth article (part 4) elucidated

the role of the microbiome in infectious diseases; the fifth article (part 5) explored respiratory conditions of the ears, nose, and throat; and the sixth article (part 6) explored the relationship between beneficial microbiota and skin disorders. The seventh article (part 7) reviewed the relationship between beneficial microbiota and autoimmune diseases, allergies, asthma, and other immunity-related disorders. This article (part 8) will explore the unique relationship between bacterial strains and gastrointestinal and genitourinary diseases associated with dysbiosis. Future articles will review the influence of the microbiome on cancer development and prognosis, followed by an article focused on probiotic supplements. This literature review is specific to disease condition, probiotic classification, and individual strain.

**Keren E. Dolan**, DCN Candidate, CNS; **Jessica M. Pizano**, DCN Candidate, CNS; **Crystal M. Gossard**, DCN Candidate, CNS; **Christy B. Williamson**, DCN Candidate, CNS; **Cathleen M. Burns**, MDCN Candidate, RD; **Margaret G. Gasta**, DCN Candidate, RDN, CCN; **Heather J. Finley**, DCN Candidate, RD, LD, CEDRD; and **Emily C. Parker**, MS, RD, are doctoral students in the doctor of clinical nutrition program; **Elizabeth A. Lipski**, PhD, CNS, BCHN, IFMCP, is a professor. All are located at Maryland University of Integrative Health in Laurel, Maryland.

Corresponding author: Heather Finley, DCN Candidate, RD, LD, E-mail address: [HeatherFinleyRD@gmail.com](mailto:HeatherFinleyRD@gmail.com)

**W**e investigated disease-specific probiotic strains associated with gastrointestinal and genitourinary diseases such as irritable bowel syndrome (IBS), Crohn's disease, *Helicobacter pylori*, bacterial vaginosis, *Candida albicans*, cystitis, prostatitis, and chronic kidney disease (CKD). This is not an exhaustive review.

The purpose of this summary is to provide nutritionists and other medical practitioners with a reference guide for recommending health-promoting commercially produced cultured and fermented food products to patients. There is considerable research on the gut microbiome and role of probiotics; however, this research has not been clearly connected with clinical practice. The authors undertook a review of current literature to explore which specific probiotics and probiotic strains have been utilized in clinical and laboratory studies.

To make this clinically valuable, product names of probiotics and fermented foods have been included. Finished products vary between manufacturers; thus, the researchers included brand listings to provide transparency and to facilitate a functional probiotics guide for clinicians. Exclusions of products meeting our criteria do not imply that these products are not effective—we simply were not aware of them.

### Methodology

This literature review originated from a group project that was part of the requirements for a course in the doctoral program in functional and clinical nutrition at Maryland

University of Integrative Health (Laurel, MD, USA). The student researchers had approximately 2 months to review the literature and synthesize the paper. The authors agreed on format, templates, and execution. Each author researched and wrote sections reviewing probiotics in relation to various health conditions with literature searches conducted in PubMed, Biomed Central, EBSCO Research Premier, PLoS One, Cochrane reviews, and topic-specific open-source journals.

The review of specific probiotic products in the professional marketplace and specific probiotics products was performed using Internet searches, primarily Shop Google, in addition to topic specific databases to search for specific probiotic species including the strains listed in the research. Novel strains were cross-referenced to determine whether the strain was available only for research purposes. If a probiotic combination was used in the research, formulas that closely matched the combination were included. Formulas that contain all or most of the specific probiotics and strains were also included. The food survey focused on bacterial strains in food and includes foods that are commercially produced and commonly available in the refrigerated sections of grocery stores in the United States. Information was gleaned from commercial Web sites, communications with food company personnel, and by visiting grocery stores (primarily in California).

Gastrointestinal diseases such as celiac disease, IBS, parasites, and Crohn's disease may be directly impacted by perturbation of the bacterial microflora. For more than a century, probiotics have been utilized clinically to help restore normal bacterial microflora and promote proper functioning of the gastrointestinal tract; however, they have been extensively researched in only recent years. Their use in the treatment and prevention of disease has provided many insightful clinical applications, which are summarized in this review. Probiotics have been clinically studied in Crohn's disease, IBS, celiac disease, and other disorders. The results of these studies are summarized in the tables.

### Research Overview: Gastrointestinal Disease

Efficacy of probiotic compounds has been shown in a wide range of gastrointestinal diseases including gastric ulcers, IBS, ulcerative colitis, celiac disease, and other inflammatory bowel diseases. *Lactobacillus* GG alone, or in the combination of *Bifidobacterium bifidum* and *Streptococcus thermophilus*, is effective in the treatment of *Clostridium difficile*. Probiotics have been used to prevent antibiotic induced diarrhea.<sup>1</sup>

Pouchitis is a common complication in patients undergoing restorative proctocolectomy for ulcerative colitis. Probiotics and prebiotics in the treatment of these patients has been proved effective when the probiotic strains *Bifidobacterium*, *Lactobacillus*, and *Saccharomyces boulardii* are utilized.<sup>2</sup> VSL#3 is a common probiotic utilized for

ulcerative colitis patients.<sup>3</sup> Profermin is also effective in reducing remission in ulcerative colitis.<sup>4</sup>

In patients with celiac disease, *Bifidobacterium infantis* provided improvement in symptoms of indigestion and constipation; *Bifidobacterium* also produced some immunologic changes but was not successful in modifying intestinal permeability.<sup>5</sup> *Bifidobacterium breve* has shown a positive effect on increasing the production of proinflammatory cytokine tumor necrosis factor alpha in children with celiac disease.<sup>6</sup> Several strains of *Lactobacillus* (*paracasei*, *rhamnosus*) show potential for the treatment of celiac disease and preventing undigested gliadin peptides toxic effects.<sup>3</sup>

In the treatment of parasites, *Bifidobacterium animalis* had an immunomodulatory action, whereas *Lactobacillus casei* and *Enterococcus faecium* were both effective at eliminating giardia infection.<sup>7,8</sup> In addition, *Aymomonas mobilis* was reported to provide 60% protection from the infection of *Schistosoma masoni* in mice.<sup>7</sup>

*Lactobacillus johnsonii*, *Saccharomyces boulardii*, *Lactobacillus acidophilus*, and *Bifidobacterium lactis* were all proven effective in treating *H pylori*. *L johnsonii* was found effective in inhibiting adhesion of *H pylori* to gastric epithelial cells and several studies have recommended *S boulardii* or *Lactobacillus* species in combination with standard triple therapy.<sup>9</sup>

Unfortunately, most studies show there is no efficacy for probiotics in Crohn's disease treatment at this time.<sup>2,3</sup>

The treatment of small intestinal bacterial overgrowth (SIBO) can be improved with probiotics. *Bifidobacterium* triple viable capsule, *B bifidum*, *B lactis*, *Bifidobacterium longum*, *L acidophilus*, *Lactobacillus rhamnosus*, *L casei*, and *Streptococcus thermophilus* are all beneficial for SIBO. There are data that show a good outcome with sequential antibiotic probiotic/prebiotic administration in patients with SIBO.<sup>10-12</sup> In patient with diarrhea-predominant IBS, dual coating capsules containing 5 billion bacteria were utilized for 4 weeks. Results indicated a significant improvement in intestinal microbiota and overall discomfort when compared with the group utilizing noncoated probiotics. Multistrain probiotics have been found best for IBS.<sup>13</sup>

It is evident that a variety of probiotic strains are helpful in combating gastrointestinal diseases, and more research is needed to evaluate other strains. The natural microbes can be found in foods as well as supplements that come in pills, capsules, powders, and liquids. Each strain has a different effect on the microbiome and offer clinical improvement for patients with IBS, ulcerative colitis, antibiotic-associated diarrhea, parasites, and SIBO with minimal risk or adverse side effects.

### Research Overview: Genitourinary

The use of probiotics for maintaining genitourinary health in males and females may be a cost-effective alternative treatment for those suffering from a variety of

**Table 1.** Gastrointestinal Disorders

Gastrointestinal Infections	Strains	Overview	Professional and Commercial Products	Foods
<p><b>Celiac Disease</b> Smecuol et al<sup>5</sup> (2013); Klemenak et al<sup>6</sup> (2015)</p> <p>Smecuol et al<sup>5</sup> (2015); Lorenzo et al<sup>14</sup> (2015)</p> <p>Sarno et al<sup>15</sup> (2014) Durchschein<sup>3</sup> (2016)</p>	<p><i>B infantis</i> NLS, <i>B breve</i> BR03, <i>B breve</i> B632, <i>B longum</i> CECT 7347</p> <p><i>L rhamnosus</i>, <i>L paracasei</i></p> <p><i>L paracasei</i> CBA L74 &amp; P31-43</p>	<p>In patients with celiac disease, <i>B infantis</i> NLS provided improvement in symptoms of indigestion and constipation; produced some immunologic changes but did not modify intestinal permeability</p> <p><i>B breve</i> BR03; <i>B breve</i> B632 has shown a positive effect on decreasing the production of pro-inflammatory cytokine TNF-<math>\alpha</math> in children with celiac disease on gluten-free diet.</p> <p><i>B longum</i> CECT7347 produces minimal changes in gut microbiota with gluten-free diet. <i>Lactobacillus</i> shows high percentages of autoaggregation and <i>Lactobacillus</i> shows high hydrophobicity, which makes them potential for treatment associated with celiac disease.</p> <p><i>L paracasei</i> CBA L74 &amp; P31-43 prevent undigested gliadin peptides toxic effects.</p> <p>Precaution: When probiotics are used, the risk of bacterial translocation and subsequent bacteremia has to be considered.</p>	<p><i>B breve</i>, <i>B longum</i>, <i>L rhamnosus</i>, <i>L paracasei</i>: Renew Life Ultimate Flora Extra Care 50 Billion</p> <p><i>B infantis</i> NLS: Natren Life Start Probiotics for Infants and Life Start Vegan, Natren</p> <p><i>B breve</i> BR03 Bifidus Balance+FOS (Jarrow Formulas)</p> <p><i>B breve</i> BR03 and B632 (Bifibaby, Probiotal Spa)</p> <p><i>B longum</i> CECT 7347 (not available)</p> <p><i>L rhamnosus</i> (common in multistrain options)</p> <p><i>L rhamnosus</i> with FOS (Swanson Ther-Biotic Factor 1, Klaire Labs)</p> <p>Gr8-Dophilus (NOW Foods)</p> <p><i>L paracasei</i> CBA L74 &amp; P31-43 (not available)</p>	<p><i>B infantis</i> NLS: None</p> <p><i>B breve</i> BR03: None</p> <p><i>B breve</i> B632, <i>B longum</i> CECT 7347, <i>L rhamnosus</i>: Kevita kombucha drinks, yogurt</p> <p><i>L paracasei</i>: Kevita probiotic drinks, Wallaby organic cow's milk yogurt</p> <p><i>L paracasei</i> CBA L74 &amp; P31-43: None</p>
<p><b>Parasites</b> Ribeiro et al<sup>8</sup> (2016); Berrilli et al<sup>7</sup> (2012)</p>	<p><i>B animalis</i> subsp <i>lactis</i></p> <p><i>L casei</i> MTCC</p> <p><i>E faecium</i> SF68</p>	<p>The probiotic <i>B animalis</i> had an immunomodulatory action, inducing CD19 lymphocyte proliferation, and consequently increasing anti-<i>T gondii</i> antibody level-B provided protection in supplemented mice.</p> <p><i>L casei</i> and <i>E faecium</i> were both effective at eliminating Giardia infection.</p> <p>Oral treatment of <i>L casei</i> appears to reduce the parasite burden <i>T spiralis</i> in mice.</p> <p><i>E faecalis</i> has inhibitory activity against Gram-positive and Gram-negative bacteria.</p> <p><i>A mobilis</i> was reported to provide 60% protection from the infection of <i>S mansoni</i> in mice.</p>	<p><i>B animalis</i> subsp <i>lactis</i> (HLC Maintenance, Pharmax)</p> <p><i>L casei</i> MTCC (not available)</p> <p><i>E faecium</i> SF68 (not available)</p>	<p><i>B animalis lactis</i>, DN-173 010/CNCM</p> <p>I-2494: Activia yogurt</p> <p><i>L casei</i> MTCC: None</p> <p><i>E faecium</i> SF68: None</p>
<p><b>H. Pylori</b> Khoder et al<sup>9</sup> (2016)</p>	<p><i>L johnsonii</i>, <i>S bouldardii</i>, <i>L acidophilus</i>, <i>B lactis</i></p>	<p><i>L johnsonii</i> inhibits adhesion of <i>H pylori</i> to gastric epithelial cells in vitro.</p> <p>Meta-analytic studies have recommended the use of either <i>S bouldardii</i> or <i>Lactobacillus</i> species supplementation in combination with the standard triple therapy.</p>	<p><i>L johnsonii</i> (not available)</p> <p><i>S bouldardii</i> (Jarrow Formulas, Biotics Research, Ortho Molecular Products, Klaire Labs, Bronson Vitamins, Pure Encapsulations, Nutricology, Kirkman Labs, Thorne Research)</p> <p><i>L acidophilus</i> and <i>B lactis</i> (widely available in commercial formulas)</p> <p>Gr8-Dophilus (NOW Foods, Ther-Biotic Factor 4: Bifidobacterium Complex, Klaire Labs, Dr Formulated Probiotics—various formulas, Garden of Life, Ultimate Flora Extra Care Probiotic, Renew Life)</p>	<p><i>L johnsonii</i>: Milk and fermented dairy products</p> <p><i>S bouldardii</i>: None</p> <p><i>L acidophilus</i>: Lassi, kefir, yogurt</p> <p><i>B lactis</i>: Almond Dream nondairy yogurt, Nancy's Organic cultured soy, goat milk yogurt, vow's milk lassi, Nancy's Organic cow's milk kefir</p>

**Table 1.** (continued)

Gastrointestinal Infections	Strains	Overview	Professional and Commercial Products	Foods
<b>Crohn's Disease</b> Durchschein et al <sup>3</sup> (2016); Lichtenstein et al <sup>2</sup> (2016)		There is no evidence for efficacy of probiotics in Crohn's disease.	None	None
<b>Bariatric Surgery</b> Tarplin <sup>16</sup> (2015)		Both pyridoxine and probiotics have been shown in small studies to reduce hyperoxaluria.		
<b>SIBO</b> Liang <sup>11</sup> (2016)  Kwak et al <sup>10</sup> (2014)  Rosania et al <sup>12</sup> (2013)	<i>Bifidobacterium</i> triple viable capsule, <i>B bifidum</i>  <i>B lactis</i> , <i>B longum</i>  <i>L acidophilus</i> , <i>L rhamnosus</i> , <i>S thermophilus</i> , <i>L casei</i>	<i>Bifidobacterium</i> triple viable capsule was effective in combatting SIBO and was associated with a significant improvement in gastrointestinal cancer related symptoms.  Short-term probiotic administration is effective in alleviating SIBO and clinical symptom.  Data show a good outcome with sequential antibiotic/probiotic/prebiotic administration in patients with SIBO.	<i>B bifidum</i> , <i>B lactis</i> , <i>B longum</i> , <i>L acidophilus</i> , <i>L rhamnosus</i> , <i>S thermophilus</i> , and <i>L casei</i> are formulated together in the following brands:  Nexabiotic (Bioprospan Labs)  Mega Probiotic-ND (Food Science)  Mega Flora Plus (Mega Food)  Iflora Multi-Probiotic Formula (Sedona Labs)  ProBiota 12 (Seeking Health)  Sehat Probiotic (Trivedi)	<i>B</i> triple viable capsule: None  <i>B bifidum</i> : Kefir, All yogurt containing "live and active cultures"  <i>B lactis</i> : Almond Dream nondairy yogurt, Nancy's Organic cultured soy, Goat milk yogurt, Cow's milk lassi, Nancy's Organic cow's milk kefir  <i>B longum</i> : None  <i>L acidophilus</i> : Lassi, kefir, yogurt <i>L rhamnosus</i> : None  <i>S thermophilus</i> : lassi, kefir, all yogurts  <i>L casei</i> : Nancy's Organic cow's milk yogurt, all kefir
<b>Ulcerative Colitis</b> Durchschein et al <sup>3</sup> (2016); Lichtenstein <sup>2</sup> (2016); Rembacken et al <sup>17</sup> (1999); Matthes et al <sup>18</sup> (2010); Krag <sup>4</sup> (2013); Orel et al <sup>19</sup> (2014)	<i>E coli</i> Nissle 1917, <i>B breve</i> VSL, <i>B infantis</i> VSL, <i>B longum</i> VSL, <i>L acidophilus</i> VSL, <i>L delbrueckii</i> subp <i>bulgaricus</i> VSL, <i>L paracasei</i> VSL, <i>L plantarum</i> VSL, <i>S thermophilus</i> VSL, <i>L plantarum</i> 299v, <i>B clausii</i> ( <i>enterogermina</i> ), <i>L casei</i> Shirota, <i>S cerevisiae</i> variety <i>boulardii</i> , <i>L casei</i> CRL 431, <i>L acidophilus</i> CRL-730	For patients with pouchitis, antibiotics treatment followed by VSL#3 or <i>Lactobacillus</i> GG is effective.  Prebiotic inulin is capable of reduction of mucosal inflammation in patients with subclinical chronic pouchitis.  When treated with nonpathogenic <i>E coli</i> , time to remission and duration of remission was equivalent to a group treated with corticosteroid.  Probiotic enemas resulted in dose-dependent remission rate.  Supplementation with profermin is safe, well tolerated, palatable, and able to reduce SCCAI scores at a statistically and clinically significant level in patients with mild-to-moderate ulcerative colitis with a flare-up.  VSL#3 and <i>E coli</i> Nissle 1917 provide strong clinical evidence for the treatment of active ulcerative colitis.	<i>E coli</i> Nissle 1917 (Mutaflor Tribute Pharmaceuticals)  VSL#3 for ulcerative colitis <sup>3</sup>  Culturelle (Digestive Health)  Culturelle Immune Health (Klaire Labs)  Culturelle (Metagenics)  Ultra Flora Intensive Care (Jarrow Ideal)  Bowel Support 299v (Ther-Biotic Factor) 4 Bifidobacterium Complex 60c by Klaire Labs ( <i>B breve</i> )	Strains in VSL: None  <i>L plantarum</i> 299v: Good Belly Probiotic Foods  <i>Bacillus clausii</i> : None  <i>L casei</i> Shirota: Yakult  <i>S cerevisiae</i> variety <i>boulardii</i> , <i>L casei</i> CRL-431, <i>L acidophilus</i> CRL -730: None

**Table 1.** (continued)

Gastrointestinal Infections	Strains	Overview	Professional and Commercial Products	Foods
<b>Irritable Bowel Syndrome</b> Han et al <sup>13</sup> (2016)	<i>L plantarum</i> 299v, <i>B animalis</i> subsp <i>lactis</i> DN-173-010, <i>B infantis</i> 35624, <i>L fermentum</i> VRI-003, <i>L plantarum</i> 299v  <i>L acidophilus</i> VSL, <i>S thermophilus</i> VSL, <i>B infantis</i> VSL, <i>B breve</i> VSL, <i>L paracasei</i> VSL, <i>B bifidum</i> CUL-20, <i>B lactis</i> CUL-34, <i>L acidophilus</i> CUL-21, <i>L acidophilus</i> CUL-60, <i>L rhamnosus</i> GG, <i>E coli</i> Nissle 1917	Dual-coating layers of probiotic supplement ( <i>Bifidobacterium</i> ) can be candidate for treatment of diarrhea-predominant IBS.	Magnetic Clay Inc Prescript Assist  Genestra HMF Pre+Probiotic Pharmax HLC Immunity+Pro Genestra  Multi+Pro F Genestra  Multi+Pro F50+ Genestra Multi+Pro M  Genestra Multi+ProM50+ Sigma Tau VSL#3 (Metagenics)  Ultra Flora Intensive Care (Jarrow Ideal)  Bowel Support 299v (Pharmanex ProBio PCC, Procter & Gamble Align, Danone Activia, GoodBelly Probiotic Drink Range, Ther-Biotic Factor4)  Bifidobacterium Complex) 60c by Klaire Labs ( <i>B breve</i> )	<i>L plantarum</i> 299v: GoodBelly Probiotic Products  <i>B animalis subsp lactis</i> DN-173-010: Activia Yogurt  <i>B infantis</i> 35624: None  <i>L fermentum</i> VRI-003: None  <i>L plantarum</i> 299v: GoodBelly Probiotic Products  VSL Strains: None  <i>B bifidum</i> CUL-20, <i>B lactis</i> CUL-34, <i>L acidophilus</i> CUL-21, <i>L acidophilus</i> CUL-60, <i>L rhamnosus</i> GG, <i>E coli</i> Nissle 1917: None

Abbreviations: IBS, irritable bowel syndrome; SIBO, small intestinal bacterial growth;

recurring genitourinary infections. For women, most *Lactobacillus* strains applied topically and containing more than 1 billion colony-forming units (CFUs) showed positive results with most bacterial vaginosis and *Candida* infections.<sup>20</sup> One in vivo study on toxic shock syndrome showed that probiotics adhered immediately to the virulent bacterial toxins produced by *Staphylococcus aureus*.<sup>21</sup> Recurrent urinary tract infections (UTIs) have been associated with depletion of vaginal *Lactobacillus*, and Stapleton et al<sup>22</sup> showed that the use of vaginal suppository of *Lactobacillus crispatus* was associated with a reduction of recurrent UTIs in women.

In men, the link between the gut microbiota and prostatitis is just now being recognized and explored in the literature, and VSL#3 combined with rifaxin to address the gut microbiota helped to greatly decrease chronic prostatitis.<sup>23</sup>

CKD is another area where probiotics may favorably affect the outcome of disease by influencing the microbiota. The intestine and the kidney influence each other's health in a complex bidirectional manner.<sup>24</sup> The intestine generates protein-bound uremic toxins, p-Cresol, and indoxylsulfate. Uremia then many cause structural and functional changes in the intestine including bacterial translocation, increased gut permeability, and generation of protein-bound uremic toxins that lead to inflammation that, in turn, causes increased morbidity and mortality in CKD and non-CKD populations.<sup>24</sup> Intestinal dysbiosis may be associated with

increased uremic toxin level that may contribute to the progression of CKD.<sup>25</sup> The intestinal microbiota in CKD patients is altered with lower levels of *Lactobacillus* and *Prevotella* species, and 100 times higher with *Enterobacteria* and *Enterococci* species.<sup>25</sup> Kidney disease is associated with factors that cause intestinal dysbiosis, including decreased fiber intake, higher antibiotic use, slower colon transit time, metabolic acidosis, volume overload with intestinal wall congestions, intestinal wall edema, and oral iron intake.<sup>25</sup> Therefore, targeting the gut microbiota with a lower protein diet and prebiotics and probiotics will help to generate fewer uremic toxins may be a credible adjuvant approach for addressing CKD and the associated high morbidity and mortality.<sup>25</sup>

There is only a small body of pilot research on the utilization of probiotics in people with CKD. According to Rossi et al,<sup>26</sup> the studies that have been done on evaluating the effects of probiotics on CKD have been poorly designed, often did not have a control group, the strains were not been selected with any clear rationale, and for the most part have shown a poor outcome on urea levels and uremic toxins. Furthermore, the population that might benefit the most, the predialysis population, has not been targeted for studies.<sup>26</sup> A pilot study of 25 people with PKD included some in stage III, with creatinine levels of 1.7, compared with other studies with only people in stages IV to V CKD. This cross-over study compared the effects on a probiotic supplement containing

*Streptococcus thermophilus* (KB19), *L. acidophilus* (KB27), and *B longum* (KB31) in subjects with diabetes versus people with CKD who did not have diabetes. Placebo and probiotic were each taken for 3 months. All subjects had reductions in blood urea levels. Only subjects without diabetes had significant stabilization or reductions in glomerular filtration rate (GFR). Approximately 54% of subjects with diabetes were taking chronic antibiotics for neurologic bladder, which may have attributed to the nonsignificant changes in GFR in the subjects with diabetes.<sup>27</sup>

At this time, no strains of probiotics have been identified that produce definite benefits in CKD patients. A study in rats showed that *Bacillus pasteurii* and *Lactobacillus sporogenes* decrease BUN and serum

creatinine. *L. casei* Shirota in high doses of 16 billion decreased BUN by 11% but not creatinine. *L. acidophilus* and *B longum* have shown a borderline decrease in BUN in only 40% of subjects.<sup>26</sup> A recent study analyzing National Health and Nutrition Survey (NHANES) data found that frequent consumption of yogurt and or probiotics use was associated with decreased risk of proteinuria kidney disease.<sup>25</sup>

As antibiotic resistance increases, it is important to consider having cost effective, evidence-based alternative treatments available such as the use of certain probiotic strains for specific recurring genitourinary infections. The use of probiotics for maintaining the health of the genitourinary tract warrants continued research.

**Table 2.** Genitourinary Disorders

Genitourinary	Strains	Overview	Professional and Commercial Products	Foods
<b>Bacterial Vaginosis</b> Coudeyras <sup>28</sup> (2008)  Mastromarino et al <sup>29</sup> (2009)  Mastromarino <sup>30</sup> (2013)  Parolin et al <sup>30</sup> (2015)  Vicariotto <sup>31</sup> (2014)	<i>L. rhamnosus</i> , <i>L. reuteri</i> (vaginally)  <i>L. brevis</i> + <i>L. salivarius</i> + <i>L. plantarum</i>  <i>L. acidophilus</i> + <i>estriol</i>	Most clinical trials using 1 billion CFU of any lactobacillus species applied externally were positive.  All strains showed cure of BV and decreased incidence of recurrence through anti-microbial action and preventing adherence of pathogen.	Femdophilus (Nature's Way contains <i>L. reuteri</i> + <i>L. rhamnosus</i> )	<i>L. rhamnosus</i> : Almond Dream nondairy yogurt, Amande cultured almond milk, Trader Joe's cultured coconut milk, Nancy's Organic cultured soy, Nancy's Organic cow's milk yogurt, all kefirs, Kevita kombucha and sparkling probiotic drinks  <i>L. brevis</i> : pickled beets, kimchi, sauerkraut, all wildbrine brand products  <i>L. plantarum</i> : fermented vegetables, Kevita probiotic drinks, olives (green)  <i>L. acidophilus</i> : lassi, kefir, yogurt  <i>L. reuteri</i> , <i>L. salivarius</i> : None
<b>Toxic Shock</b> Younes <sup>21</sup> (2012)	<i>L. reuteri</i> RC-14 (4.0-6.4 nN)	Shown to adhere to three virulent toxic shock syndrome toxin 1-producing.  <i>S. aureus</i> strains, demonstrating the potential for rapid antipathogen effects.		None
<b>Candida Albicans</b> De Seta et al <sup>32</sup> (2014)	<i>L. plantarum vaginal</i>	Cure and decreased incidence of recurrence.	Widely available	<i>L. plantarum</i> : fermented vegetables, Kevita, probiotic drinks, olives (green)

**Table 2.** (continued)

Genitourinary	Strains	Overview	Professional and Commercial Products	Foods
<p><b>Cystitis</b> Stapleton et al<sup>22</sup> (2011)</p> <p>Uehara et al<sup>33</sup> (2006)</p> <p>Vicariotto<sup>21</sup> (2014)</p>	<p><i>L crispatus</i></p> <p><i>L plantarum</i> + <i>S thermophilus</i> + <i>L paracasei</i> + <i>mannose</i> + <i>Tara</i></p>	<p><i>L crispatus</i> resulted in significant reduction in recurrent UTIs.</p> <p><i>L plantarum</i>, <i>S thermophilus</i>, <i>L paracasei</i>, mannose, and Tara treatment resulted in decreased adhesion of bacteria, significantly reduced positive nitrites and leukocyte esterase and negative results after 60 d. Typical symptoms of cystitis significantly decreased.</p>	<p><i>L crispatus</i> (not found)</p> <p>Other strains ubiquitous in many multistrain probiotics</p>	<p><i>L plantarum</i>: fermented vegetables, Kevita probiotic drinks, olives (green)</p> <p><i>S thermophilus</i>: All yogurts and kefirs containing “live active cultures”</p> <p><i>L paracasei</i> Kevita probiotic drinks, Wallaby organic cow’s milk yogurt</p> <p><i>L crispatus</i>: None</p>
<p><b>Prostatitis</b> Vicari et al<sup>23</sup> (2014)</p>	<p>VS#3: <i>B longum</i>, <i>B infantis</i>, <i>B breve</i>, <i>L acidophilus</i>, <i>L casei</i>, <i>L delbrueckii</i>, <i>L bulgaricus</i>, <i>L plantarum</i>, <i>S salivarius</i> subsp <i>thermophiles</i>) + Rifaxim (IBS + CP)</p>	<p>Men with chronic prostatitis and IBS were treated with VSL#3 and rifaxin with the hypothesis that gut dysbiosis may be a factor in chronic prostatitis. The treatment lowered the frequency of bacteriospermia.</p>	<p>Ther-Biotic Factor 4 (Bifidobacterium Complex) 60c by Klaire Labs (<i>B breve</i>)</p> <p><i>L plantarum</i>: Jarrow Formulas Ideal Bowel Support, 10 Billion Organisms V-Capsules</p> <p>Probiotic Supplement (GoodBelly)</p> <p>Probiotic GX (Nature’s Bounty)</p> <p>Probiata Digestion Support and Critical Care (Kyolic)</p> <p>Probiotic Balance (Sundown Naturals)</p> <p>Heart Healthy Probiotic Solutions (Dr Sinatra)</p> <p>Digestive Health Probiotic (Nature Made)</p>	<p>Specific VSL#3 strains: None</p>
<p><b>Kidney Stones/Hyperoxaluria</b> Barnett et al<sup>34</sup> (2016)</p>	<p><i>O formigenes</i></p>	<p><i>O formigenes</i> is commonly found in the human microbiome where it uses oxalates for energy. This Gram-negative anaerobic bacterium helps to increase intestinal absorption of oxalates and ultimately urinary oxalate excretion. This bacterial species, unfortunately, is quite susceptible to commonly prescribed antibiotics which will decrease an individual’s level of this beneficial species and increase oxalate levels which may lead to an increased risk for kidney stones.</p>	<p>None</p>	<p>None</p>

**Table 2.** (continued)

Genitourinary	Strains	Overview	Professional and Commercial Products	Foods
<b>Chronic Kidney Disease</b> Rossi et al <sup>26</sup> (2014)  Vanholder et al <sup>24</sup> (2015)  Pavan <sup>35</sup> (2016)  Ranganathan et al <sup>36</sup> (2017)  Awn et al <sup>27</sup> (2016)	<i>B pasteurii</i> + <i>L sporanges</i>	<i>B pasteurii</i> + <i>L sporogenes</i> showed a decrease in BUN and serum creatinine in rats.	Thorne Bacillus Coagulans (contains <i>L sporogenes</i> )	<i>B pasteurii</i> + <i>L sporanges</i> : None
	<i>L casei</i> Shirota	<i>L casei</i> Shirota in higher doses (16 billion CFU showed a small 11% decrease in BUN but not serum creatinine).	Energetics Flora Chewable— <i>L sporogenes</i> ( <i>B coagulans</i> )	<i>L casei</i> Shirota: Yakult
	<i>L acidophilus</i> + <i>B longum</i>	<i>L acidophilus</i> and <i>B longum</i> have shown a small, borderline significant decrease in BUN in 40% of subjects.	Energetics Flora Synergy ( <i>L sporogenes</i> )	<i>L acidophilus</i> : Lassi, kefir, yogurt
	<i>S thermophiles</i> , <i>L acidophilus</i> , <i>B longum</i> + <i>F saccharides</i>	<i>S thermophiles</i> , <i>L acidophilus</i> , <i>B longum</i> (all at dosages of 15 billion CFU), plus fructooligosaccharids 100 mg given to patients with CKD stable in stages III to V. in open label RCT. Patients on low-protein diet plus pro- and prebiotics demonstrated a nonsignificant decline in GFR than in control group on low-protein diet alone over 1 y. There were no changes in blood pressure, hemoglobin, calcium, phosphorus, or albumin.	Pure Encapsulations ( <i>L sporogenes</i> )	<i>B longum</i> : None
	<i>S thermophilus</i> (KB19), <i>L acidophilus</i> (KB27) + <i>B longum</i> (KB31)	214 people with CKD responded to survey or product users and independently analyzed. Average use: 2.05 y. Longest 7 y, shortest 6 m. Reported stabilization, or decreased progression of GFR which improved with time.	Widely available	<i>S thermophilus</i> . Yogurt; fermented milk products
<i>S thermophilus</i> (KB19), <i>L acidophilus</i> (KB27) + <i>B longum</i> (KB31)	25 patients with CKD, stages III to IV, treated in a cross-over study for 3 mo each of placebo or probiotic. Significant reductions in blood urea on probiotic in diabetic and nondiabetic subjects. Significant reductions in serum creatinine levels in nondiabetic subjects, but in diabetic group, changes in serum creatinine were not significant. Differences may be due to antibiotics in diabetic patients on chronic antibiotics for neurologic bladder.	Kibow Tech: Renadyl		
	In summary, only pilot studies and poor research has been conducted in this area showing conflicting outcomes. See the overview.	Kibow Tech: Renadyl		

Abbreviations: IBS, irritable bowel syndrome; SIBO, small intestinal bacterial overgrowth; UTI, urinary tract infection; CKD, chronic kidney disease; RCT, randomized clinical trial.

### Nutritional Supplements Overview

Professional and commercial dietary supplements containing probiotics are widely available.<sup>37-42</sup> In 2002, it was estimated that more than 100 companies in the United States marketed probiotic supplements, and nearly 2 million adults consume them regularly.<sup>38</sup> In 2012, probiotic or prebiotic use was the third most commonly used nonvitamin, nonmineral dietary supplement, and global sales were projected to reach to \$42 billion by the end of 2016.<sup>39</sup> Using probiotics for general health versus targeting a specific health concern is more complex as the properties of probiotic species are strain specific.<sup>40</sup> Unfortunately, research models lack consistency in naming therapeutic strains while in addition, specific strains are often not listed on supplement labels. This challenge prevents the practitioner from distinguishing the researched strain from the supplemental product and is a limitation of these tables. If the researched strain was not readily available on the label or marketing material, the brand, potentially containing the strain, was not included in the table.

The Joint Food and Agriculture Organization of the United Nations/World Health Organization Expert Consultation on Evaluation of Health and Nutritional

Properties of Probiotics developed guidelines for evaluating probiotics in food. A combination of phenotypic and genotypic tests must be performed to determine the strain; however, regulations on species identification is not in place and supplement companies are not required to list this information on labels. During this multiseries review, it was identified that 30 species were specifically isolated for research purposes and were unavailable and another 56 strains were not commercially available. Due to the wide variety of formulations on the market, lack of knowledge, and poor labeling, it is difficult for practitioners and consumers to determine which brand contains specific strains researched to address a particular health concern.

This table is designed to be a resource to see what is available “at-a-glance.” The brands were chosen by searching the probiotic strain and strain-species in Google, several supplement companies, Probiotics Advisor,<sup>41</sup> and the Clinical Guide to Probiotic Products.<sup>42</sup> Based on the results and to determine what was commercially available, the search was refined using Google Shopping. In some instances, the supplement company was called to determine whether the formula contained a specific species.

**Table 3.** Supplemental Information on Gastrointestinal and Genitourinary Disorders

Disease	Supplement	Probiotic Strain(s)
Celiac Disease	Bifibaby, Probiotal Spa	<i>B breve</i> BR03 and B632
Celiac Disease	Bifidus Balance+FOS (Jarrow Formulas)	<i>B breve</i> BR03
Celiac Disease	Natren Life Start Probiotics for Infants and Life Start Vegan (Natren)	<i>B infantis</i> NLS
Celiac Disease	Not available	<i>B longum</i> CECT 7347
Celiac Disease	Not available	<i>L paracasei</i> CBA L74 & P31-43
Celiac Disease	Renew Life Ultimate Flora Extra Care 50 Billion	<i>B breve</i> , <i>B longum</i> , <i>L rhamnosus</i> , <i>L paracasei</i>
Celiac Disease	Widely available	<i>L rhamnosus</i>
<i>H pylori</i>	Biotics Research	<i>S boulardii</i>
<i>H pylori</i>	Bronson Vitamins	<i>S boulardii</i>
<i>H pylori</i>	Jarrow Formulas	<i>S boulardii</i>
<i>H pylori</i>	Kirkman Labs	<i>S boulardii</i>
<i>H pylori</i>	Klaire Labs	<i>S boulardii</i>
<i>H pylori</i>	Not available	<i>L johnsonii</i>
<i>H pylori</i>	Nutricology	<i>S boulardii</i>
<i>H pylori</i>	Ortho Molecular Products	<i>S boulardii</i>
<i>H pylori</i>	Pure Encapsulations	<i>S boulardii</i>
<i>H pylori</i>	Thorne Research	<i>S boulardii</i>
<i>H pylori</i>	Widely available in commercial formulas	<i>L acidophilus</i> and <i>B lactis</i>
Irritable Bowel Disease	Digestive Health Probiotic (Nature Made)	<i>L plantarum</i> 299v
Irritable Bowel Disease	Heart Healthy Probiotic Solutions (Dr Sinatra)	<i>L plantarum</i> 299v
Irritable Bowel Disease	Ideal Bowel Support (Jarrow Formulas)	<i>L plantarum</i> 299v
Irritable Bowel Disease	Probiata Digestion Support and Critical Care (Kyolic)	<i>L plantarum</i> 299v
Irritable Bowel Disease	Probiotic Balance (Sundown Naturals)	<i>L plantarum</i> 299v
Irritable Bowel Disease	Probiotic GX (Nature's Bounty)	<i>L plantarum</i> 299v
Irritable Bowel Disease	Probiotic Supplement (GoodBelly)	<i>L plantarum</i> 299v
Irritable Bowel Disease	Activia yogurt	<i>B animalis</i> subsp <i>lactis</i> DN-173-010
Irritable Bowel Disease	Align Probiotics (Proctor & Gamble)	<i>B infantis</i> 35624
Irritable Bowel Disease	Probiomics Ltd, Sydney, Australia	<i>L fermentum</i> VRI-003
Irritable Bowel Disease	VSL#3 (Sigma Tau)	<i>L acidophilus</i> VSL
Irritable Bowel Disease	VSL#3 (Sigma Tau)	<i>S thermophilus</i> VSL
Irritable Bowel Disease	VSL#3 (Sigma Tau)	<i>B infantis</i> VSL

**Table 3.** (continued)

Disease	Supplement	Probiotic Strain(s)
Irritable Bowel Disease	VSL#3 (Sigma Tau)	<i>B breve</i> VSL
Irritable Bowel Disease	VSL#3 (Sigma Tau)	<i>L paracasei</i> VSL
Irritable Bowel Disease	HMF (Genestra)	<i>B bifidum</i> CUL-20
Irritable Bowel Disease	Ultra Probiotic Complex (GNC)	<i>B bifidum</i> CUL-20
Irritable Bowel Disease	HMF Fit for School	<i>B bifidum</i> CUL-20
Irritable Bowel Disease	HMF (Genestra)	<i>B lactis</i> CUL-34
Irritable Bowel Disease	Ultra Probiotic Complex (GNC)	<i>B lactis</i> CUL-34
Irritable Bowel Disease	HMF Fit for School	<i>B lactis</i> CUL-34
Parasites	HLC Maintenance (Pharmax)	<i>B animalis</i> subp <i>lactis</i>
Parasites	Not available	<i>L casei</i> MTCC
Parasites	Not available	<i>E faecium</i> SF68
SIBO	lflora Multi-Probiotic Formula (Sedona Labs)	<i>B bifidum</i> , <i>B lactis</i> , <i>B longum</i> , <i>L acidophilus</i> , <i>L rhamnosus</i> , <i>S thermophilus</i> , and <i>L casei</i>
SIBO	Mega Flora Plus (Mega Food)	<i>B bifidum</i> , <i>B lactis</i> , <i>B longum</i> , <i>L acidophilus</i> , <i>L rhamnosus</i> , <i>S thermophilus</i> , and <i>L casei</i>
SIBO	Mega Probiotic-ND (Food Science)	<i>B bifidum</i> , <i>B lactis</i> , <i>B longum</i> , <i>L acidophilus</i> , <i>L rhamnosus</i> , <i>S thermophilus</i> , and <i>L casei</i>
SIBO	Nexabiotic (Bioprospers Labs)	<i>B bifidum</i> , <i>B lactis</i> , <i>B longum</i> , <i>L acidophilus</i> , <i>L rhamnosus</i> , <i>S thermophilus</i> , and <i>L casei</i>
SIBO	ProBiota 12 (Seeking Health)	<i>B bifidum</i> , <i>B lactis</i> , <i>B longum</i> , <i>L acidophilus</i> , <i>L rhamnosus</i> , <i>S thermophilus</i> , and <i>L casei</i>
SIBO	Sehat Probiotic (Trivedi)	<i>B bifidum</i> , <i>B lactis</i> , <i>B longum</i> , <i>L acidophilus</i> , <i>L rhamnosus</i> , <i>S thermophilus</i> , and <i>L casei</i>
Ulcerative Colitis	Jarrow Ideal Bowel Support 299v	<i>L plantarum</i> 299v
Ulcerative Colitis	Mutaflor (Tribute Pharmaceuticals)	<i>E coli</i> Nissle 1917
Ulcerative Colitis	Ther-Biotic Factor 4 (Klaire Labs)	<i>B breve</i>
Ulcerative Colitis	VSL#3 (Sigma-tau Pharmaceuticals, Inc)	VSL#3, <i>B longum</i> , <i>B infantis</i> , <i>B breve</i> , <i>L acidophilus</i> , <i>L casei</i> , <i>L delbrueckii</i> , <i>L bulgaricus</i> , <i>L plantarum</i> , <i>S salivarius</i> subsp <i>hermophiles</i>
Bacterial Vaginosis	Advanced Probiotic 10 (Nature's Bounty)	<i>L brevis</i> + <i>L salivarius</i> + <i>L plantarum</i>
Bacterial Vaginosis	Complete Probiotics (Dr Mercola)	<i>L brevis</i> + <i>L salivarius</i> + <i>L plantarum</i>
Bacterial Vaginosis	Femdophilus (Nature's Way)	<i>L reuteri</i> + <i>L rhamnosus</i>
Bacterial Vaginosis	Flora 20-14 (Innate Response)	<i>L brevis</i> + <i>L salivarius</i> + <i>L plantarum</i>
Bacterial Vaginosis	Flora 50-14 (Innate Response)	<i>L brevis</i> + <i>L salivarius</i> + <i>L plantarum</i>
Bacterial Vaginosis	lflora Multi-Probiotic Formula (Sedona Labs)	<i>L brevis</i> + <i>L salivarius</i> + <i>L plantarum</i>
Bacterial Vaginosis	Mega Flora (Mega Food)	<i>L brevis</i> + <i>L salivarius</i> + <i>L plantarum</i>
Bacterial Vaginosis	Nexabiotic (Bioprospers Labs)	<i>L brevis</i> + <i>L salivarius</i> + <i>L plantarum</i>
<i>Candida albicans</i>	Widely available in commercial brands	<i>L. plantarum vaginal</i>
Cervical	Isolated for research purposes only	LC9018 (a biologic response modifier prepared from heat-killed <i>L casei</i> YIT9018)
Chronic Kidney Disease	Energetics Flora Chewable	<i>L sporogenes</i> ( <i>B coagulans</i> )
Chronic Kidney Disease	Energetics Flora Synergy	<i>L sporogenes</i> ( <i>B coagulans</i> )
Chronic Kidney Disease	Kibow Tech Renadyl	<i>S thermophilus</i> (KB19), <i>L acidophilus</i> (KB27), <i>B longum</i> (KB31)
Chronic Kidney Disease	Not available	<i>B pasteurii</i>
Chronic Kidney Disease	Not Available	<i>L casei</i> Shirota
Chronic Kidney Disease	Pure Encapsulations	<i>L sporogenes</i> ( <i>B coagulans</i> )
Chronic Kidney Disease	Thorne	<i>L sporogenes</i> ( <i>B coagulans</i> )
Chronic Kidney Disease	Widely Available	<i>L acidophilus</i> + <i>B longum</i>
Cystitis	Not available	<i>L crispatus</i>
Cystitis	Widely available	<i>L plantarum</i> + <i>S thermophilus</i> + <i>L paracasei</i> +mannose+Tara
Kidney Stones/ Hyperoxaluria	Not available	<i>O formigenes</i>
Prostatitis	VSL3 (Sigma-tau Pharmaceuticals, Inc)	<i>B longum</i> , <i>B infantis</i> , <i>B breve</i> , <i>L acidophilus</i> , <i>L casei</i> , <i>L delbrueckii</i> , <i>L bulgaricus</i> , <i>L plantarum</i> , and <i>S salivarius</i> subsp <i>thermophiles</i>
Toxic Shock	OptiBac Probiotics for Women (Wren Laboratories)	<i>L reuteri</i> RC-14 (4.0-6.4 nN)

Abbreviation: SIBO, small intestinal bacterial overgrowth.

## References

- Madsen L, Cornish A, Soper P, et al. Probiotic bacteria enhance murine and human intestinal epithelial barrier function. *Gastroenterology*. 2001;121(3):580-591.
- Lichtenstein L, Avni-Biron I, Ben-Bassat O. Probiotics and prebiotics in Crohn's disease therapies. *Best Pract Res Clin Gastroenterol*. 2016;30(1):81-88.
- Durchschein F, Petritsch W, Hammer HF. Diet therapy for inflammatory bowel diseases: The established and the new. *World J Gastroenterol*. 2016;22(7):2179-2194.
- Krag A, Munkholm P, Israelsen H, von Ryberg B, Andersen KK, Bendtsen F. Profermin is efficacious in patients with active ulcerative colitis: A randomized controlled trial. *Inflamm Bowel Dis*. 2013;19(12):2584-2592.
- Smecul E, Hwang HJ, Sugai E, Corso L, et al. Exploratory, randomized, double-blind, placebo-controlled study on the effects of Bifidobacterium infantis naten life start strain super strain in active celiac disease. *J Clin Gastroenterol*. 2013;47(2):139-147.
- Klemenak M, Dolinsek J, Langerholc T, Di Gioia D, Micetic-Turk D. Administration of Bifidobacterium breve decreases the production of TNF-alpha in children with celiac disease. *Dig Dis Sci*. 2015;60(11):3386-3392.
- Berrilli F, Di Cave D, Cavallero S, D'Amelio S. Interactions between parasites and microbial communities in the human gut. *Front Cell Infect Microbiol*. 2012;2:141.
- Ribeiro Cde M, Zorgi NE, Meireles LR, Garcia JL, Andrade HF. CD19 lymphocyte proliferation induced by Bifidobacterium animalis subsp. lactis in C57bl/6 mice experimentally infected with Toxoplasma gondii. *Rev Inst Med Trop Sao Paulo*. 2016;58: 26.
- Khodor G, Al-Menhali AA, Al-Yassir F, Karam SM. Potential role of probiotics in the management of gastric ulcer. *Exp Ther Med*. 2016;12(1):3-17.
- Kwak DS, Jun DW, Seo JG, et al. Short-term probiotic therapy alleviates small intestinal bacterial overgrowth, but does not improve intestinal permeability in chronic liver disease. *Eur J Gastroenterol Hepatol*. 2014;26(12):1353-1359.
- Liang S, Xu L, Zhang D, Wu Z. Effect of probiotics on small intestinal bacterial overgrowth in patients with gastric and colorectal cancer. *Turk J Gastroenterol*. 2016;27(3):227-232.
- Rosania R, Giorgio F, Principi M, Amoroso A, Monno R, Di Leo A, Ierardi E. Effect of probiotic or prebiotic supplementation on antibiotic therapy in the small intestinal bacterial overgrowth: a comparative evaluation. *Curr Clin Pharmacol*. 2013 May;8(2):169-72.
- Han K, Wang J, Seo JG, Kim H. Efficacy of double-coated probiotics for irritable bowel syndrome: A randomized double-blind controlled trial. *J Gastroenterol*. 2017;52(4):432-443.
- Lorenzo Pisarello MJ, Vintiñi EO, González SN, Pagani F, Medina MS. Decrease in lactobacilli in the intestinal microbiota of celiac children with a gluten-free diet, and selection of potentially probiotic strains. *Can J Microbiol*. 2015 Jan;61(1):32-7. doi: 10.1139/cjcm-2014-0472.
- Sarno, M., Lania, G., Cuomo, M., Nigro, F., Passannanti, F., Budelli, A., Nanayakkara, M. Lactobacillus paracasei CBA L74 interferes with gliadin peptides entrance in Caco-2 cells. *Int J Food Sci Nutr*, 65(8), 953-959. doi:10.3109/09637486.2014.940283.
- Tarplin S, Ganesan V, Monga M. Stone formation and management after bariatric surgery. *Nat Rev Urol*. 2015 May;12(5):263-70. doi: 10.1038/nrurol.2015.67. Epub 2015 Apr 7.
- Rembacken, BJ, Snelling, AM, Hawkey, PM, Chalmers, DM, Axon, AT. Non-pathogenic Escherichia coli versus mesalazine for the treatment of ulcerative colitis: a randomised trial. *Lancet*, 1999;354(9179):635-639.
- Matthes, H., Krummenerl, T., Gleich, M., Wolff, C., Schulze, J. (2010). Clinical Trial; probiotic treatment of acute distal ulcerative colitis with rectally administered Escherichia Coli Nissle 1917 (EcN). *BMC Complementary and Alternative Medicine*, (10)13.
- Orel R, Kamhi Trop T. Intestinal microbiota, probiotics and prebiotics in inflammatory bowel disease. *World J Gastroenterol*. 2014 Sep 7;20(33):11505-24. doi: 10.3748/wjg.v20.i33.11505.
- Mastromarino P, Vitali B, Mosca L. Bacterial vaginosis: A review on clinical trials with probiotics. *New Microbiol*. 2013;36(3):229-238.
- Younes JA, van der Mei HC, van den Heuvel E, Busscher HJ, Reid G. Adhesion forces and coaggregation between vaginal staphylococci and lactobacilli. *PLoS One*. 2012;7(5):e36917.
- Stapleton AE, Au-Yeung M, Hooton TM, et al. Randomized, placebo-controlled phase 2 trial of a Lactobacillus crispatus probiotic given intravaginally for prevention of recurrent urinary tract infection. *Clin Infect Dis*. 2011;52(10):1212-1217.
- Vicari E, La Vignera S, Castiglione R, Condorelli RA, Vicari LO, Calogero AE. Chronic bacterial prostatitis and irritable bowel syndrome: Effectiveness of treatment with rifaximin followed by the probiotic VSL#3. *Asian J Androl*. 2014;16(5):735-739.
- Vanholder R, Glorieux G. The intestine and the kidneys: A bad marriage can be hazardous. *Clin Kidney J*. 2015;8(2):168-179.
- Khodor S, Shatar I. Gut microbiome and kidney disease: A bidirectional relationship. *Pediatr Nephrol*. 2017;32(6):921-931.
- Rossi M, Johnson DW, Morrison M, et al. Synbiotics Easing Renal failure by improving Gut microbiology (SYNERGY): A protocol of placebo-controlled randomised cross-over trial. *BMC Nephrol*. 2014;15:106.
- Awn A, Sharif D, Al-Quais RAA. The beneficial effect of renadyl (kibow) probiotics on patients with chronic kidney diseases, with comparison between diabetic and nondiabetic patients. *International J Adv Sci EngineerTech*. 2016;3:1.
- Coudeyras, S., Jugie, G., Vermerie, M., & Forestier, C. (2008). Adhesion of human probiotic Lactobacillus rhamnosus to cervical and vaginal cells and interaction with vaginosis-associated pathogens. *Infect Dis Obstet Gynecol*, 2008, 549640. doi:10.1155/2008/549640.
- Mastromarino P, Macchia S, Meggiorini L, Trinchieri V, Mosca L, Perluigi M, Midulla C. Effectiveness of Lactobacillus-containing vaginal tablets in the treatment of symptomatic bacterial vaginosis. *Clin Microbiol Infect*. 15(1): 67-74. doi:10.1111/j.1469-0691.2008.02112.x
- Parolin, C., Marangoni, A., Laghi, L., Foschi, C., Nahui Palomino, RA, Calonghi, N, Vitali, B. Isolation of Vaginal Lactobacilli and Characterization of Anti-Candida Activity. *PLoS One*. 2015;10(6):e0131220. doi:10.1371/journal.pone.0131220.
- Vicariotto, F. (2014). Effectiveness of an association of a cranberry dry extract, D-mannose, and the two microorganisms Lactobacillus plantarum LP01 and Lactobacillus paracasei LPC09 in women affected by cystitis: a pilot study. *J Clin Gastroenterol*. 48 Suppl 1, S96-101. doi:10.1097/mcg.0000000000000224
- De Seta, F, Parazzini, F, De Leo, R, Banco, R, Maso, GP, De Santo, D, Restaino, S. Lactobacillus plantarum P17630 for preventing Candida vaginitis recurrence: a retrospective comparative study. *Eur J Obstet Gynecol Reprod Biol*. 2014(182), 136-139. doi:10.1016/j.ejogrb.2014.09.018.
- Uehara, S, Monden, K, Nomoto, K, Seno, Y, Kariyama, R, Kumon, H. A pilot study evaluating the safety and effectiveness of Lactobacillus vaginal suppositories in patients with recurrent urinary tract infection. *Int J Antimicrob Agents*. 2016;28(Suppl 1):S30-34. doi:10.1016/j.ijantimicag.2006.05.008.
- Barnett C, Nazzal L, Goldfarb DS, Blaser MJ. The Presence of Oxalobacter formigenes in the Microbiome of Healthy Young Adults. *J Urol*. 2016;195(2):499-506. doi: 10.1016/j.juro.2015.08.070. Epub 2015 Aug 17.
- Pavan M. Influence of prebiotic and probiotic supplementation on the progression of chronic kidney disease. *Minerva Urol Nefrol*. 2016; 68(4):222-6. Epub 2014 Jul 3.
- Ranganathan, N., D'Silva, H., Vyas, U., Pechenyak, B., Weinberg, A., Quality of Life in Chronic Kidney Disease Patients Using a Synbiotic Dietary Supplement: A Survey. 2017. *International J. of Res Studies in Med. and Health Sci*. 2(1); 1-26 <http://dx.doi.org/10.22259/ijrms.0201004>
- Sanders ME. Probiotics, strains matter. *Funct Foods Nutraceut Mag*. 2008;48:36-41.
- Clarke TC, Black LI, Stussman BJ, Barnes PM, Nahin RL. Trends in the use of complementary health approaches among adults: United States, 2002–2012. National health statistics reports; no 79. Hyattsville, MD: National Center for Health Statistics. 2015. (240KB PDF). <https://nces.nih.gov/research/statistics/NHIS/2012/natural-products/biotics/>.
- Berkeley Wellness. Probiotics pros and cons. <http://www.berkeleywellness.com/supplements/other-supplements/article/probiotics-pros-and-cons>. Published March 3, 2014. Accessed December 24, 2016.
- Venugopalan V, Shriner KA, Wong-Beringer A. Regulatory oversight and safety of probiotic use. *Emerg Infect Dis*. 2010;16(11):1661-1665.
- Hawrelak J. Probiotic advisor. <https://www.probioticadvisor.com/>. Published 2015. Accessed December 24, 2016.
- Skokovic-Sunjic D. Clinical guide to probiotic products. <http://usprobioticguide.com/>. Published 2016. Accessed December 24, 2016.